precursor
b
acut
lymphoblast
leukemia
preb
all
abnorm
express
specif
glycan
structur
sialic
acid
cell
surfac
glycoprotein
carri
modif
identifi
use
three
differ
lectin
specif
recogn
structur
establish
nucleolin
ncl
protein
implic
cancer
contain
surprisingli
antibodi
glycolipid
also
detect
ncl
ncl
present
surfac
preb
cell
sialoglycoprotein
partli
convers
structur
ncl
present
cell
well
interestingli
ncl
signal
less
coloc
normal
preb
cell
also
investig
regul
ncl
cell
surfac
found
sialidas
treatment
increas
percentag
cell
posit
cell
surfac
ncl
suggest
sialyl
ncl
promot
intern
treatment
preb
cell
chemotherapi
drug
vincristin
also
increas
percentag
cell
surfac
ncl
correl
increas
express
test
leukemia
cell
includ
primari
sampl
express
ncl
suggest
possibl
therapeut
target
confirm
show
inhibit
cell
prolifer
preb
all
exposur
nclspecif
aptam
precursor
bcell
acut
lymphoblast
leukemia
preb
preval
malign
childhood
cell
surfac
structur
select
identifi
leukemia
cell
could
use
diagnosi
perhap
even
treatment
therefor
previou
studi
report
increas
express
specif
glycan
structur
preb
cell
consist
sialic
acid
modifi
signific
interest
context
sialic
acid
sia
belong
famili
carboxyl
monosaccharid
frequent
found
termin
residu
glycoconjug
includ
glycoprotein
glycolipid
sia
often
highli
express
cancer
moreov
chang
sialyl
promot
cancer
progress
sialic
acid
carri
modif
oacetyl
common
preferenti
occur
hydroxyl
group
carbon
yield
sialic
acid
modifi
oacetyl
express
tissu
cellspecif
manner
glycoprotein
glycolipid
normal
cell
modifi
sia
act
select
receptor
entri
virus
howev
abnorm
express
sialic
acidcontain
glycoconjug
oacetyl
deriv
also
note
correl
tumorigenesi
exampl
gangliosid
tumorspecif
marker
neuroblastoma
antibodi
current
part
mainten
therapi
pediatr
malign
interestingli
form
may
specif
treatment
target
gangliosid
form
also
call
sialyl
glycolipid
express
glioblastoma
melanoma
termin
sia
oacetyl
occur
termin
sia
residu
publish
xx
xx
xxxx
open
wwwnaturecomscientificreport
previous
report
express
preb
cell
use
antibodi
lectin
cancer
antennariu
cca
lectin
moreov
show
cell
surfac
express
correl
drug
resist
tissu
cocultur
model
presenc
stromal
protect
cell
surviv
mice
cca
lectin
bind
sialoglycoprotein
gangliosid
thu
abl
determin
unambigu
preb
cell
express
howev
infer
presenc
base
find
cca
lectin
still
bound
surfac
cell
lack
function
sialyltransferas
known
abl
gener
current
studi
undertaken
identifi
sialoglycoprotein
report
nucleolin
ncl
express
surfac
preb
cell
sialoglycoprotein
modifi
ncl
enzymat
function
best
describ
multifunct
sens
multipl
subcellular
locat
nucleusnucleolu
cytoplasm
plasma
membran
bind
multipl
biomolecul
rna
protein
implic
varieti
biolog
process
includ
angiogenesi
migrat
apoptosi
regul
cell
size
increas
ncl
express
associ
wors
prognosi
among
other
acut
myeloid
leukemia
chronic
lymphocyt
leukemia
diffus
larg
bcell
lymphoma
pancreat
ductal
cancer
interestingli
ncl
view
target
cancer
therapi
studi
show
preb
cell
sensit
antincl
treatment
use
dna
aptam
specif
bind
ncl
identifi
oacetyl
sialoglycoprotein
preb
cell
appli
total
cell
lysat
human
patientderiv
preb
cca
lectin
affin
column
silver
stain
gel
elut
fraction
show
major
band
includ
protein
around
kda
fig
top
elut
pattern
lysat
differ
preb
similar
shown
proteom
analysi
subsequ
identifi
ncl
main
compon
approxim
kda
hereaft
refer
kda
bind
cca
lectin
fig
tabl
next
examin
repres
differ
subcategori
preb
determin
ncl
express
vari
sampl
use
total
cell
lysat
western
blot
fig
c
ncl
detect
compar
level
kda
kda
core
protein
sampl
smaller
product
repres
isoform
proteolyt
product
also
detect
agreement
metaanalysi
larg
gene
express
array
data
set
includ
almost
preb
all
also
show
high
express
level
ncl
mrna
supplementari
fig
analyz
ncl
carri
sialoglycan
preb
treat
fraction
cell
lysat
elut
cca
lectin
column
peptid
nglycosidas
f
pngase
f
osialoglycoproteas
osgpas
treatment
pngase
f
cleav
nlink
glycan
replac
kda
ncl
band
kda
band
indic
cca
lectinbind
ncl
contain
nlink
glycan
fig
addit
analyz
bind
ncl
lectin
sna
sambucu
nigra
select
detect
sialic
acid
attach
nlink
glycan
kda
ncl
band
found
flowthrough
well
elut
fraction
indic
sia
attach
via
linkag
ncl
supplementari
fig
kda
ncl
glycoform
captur
cca
lectin
column
reduc
size
treatment
osgpas
fig
enzym
digest
protein
cluster
patch
olink
sialoglycan
present
sialomucin
interestingli
treatment
cca
lectin
column
fraction
c
perfringen
sialidas
reduc
molecular
mass
flowthrough
non
oacsia
well
entir
kda
cca
lectinbind
oacsia
ncl
fraction
around
kda
fig
right
panel
suggest
kda
ncl
glycoform
sialyl
proteolyt
product
smaller
fulllength
ncl
also
seen
fig
confirm
kda
ncl
sialyl
treatment
unfraction
ripa
buffer
cell
lysat
sialidas
supplementari
fig
numer
monoclon
antibodi
mab
avail
specif
recogn
howev
clear
exclus
react
gangliosid
found
mab
gener
also
detect
numer
protein
western
blot
ie
flowthrough
lane
fig
left
panel
interestingli
antibodi
specif
react
limit
number
protein
one
kda
well
kda
protein
captur
cca
lectin
column
lane
e
upon
sialidas
treatment
kda
band
disappear
antibodi
detect
doublet
around
kda
fig
right
panel
support
find
ncl
sialoglycoprotein
test
two
nidoviru
lectin
recogn
recombin
porcin
toroviru
mut
lectin
primarili
detect
modifi
sialic
acid
wherea
bovin
mut
lectin
also
detect
larg
insensit
linkag
sia
esteras
moieti
probe
mutat
inactiv
esteras
activ
tag
fusion
human
similar
cca
lectin
affin
column
column
porcin
toroviru
bovin
coronaviru
hefc
retain
kda
ncl
protein
fig
also
immunoprecipit
ncl
lysat
cell
reaction
membran
ncl
antibodi
confirm
immunoprecipit
retent
membran
fig
lower
panel
antibodi
detect
ncl
fig
upper
panel
triplic
western
blot
incub
either
porcin
wt
fc
porcin
mut
fc
control
buffer
wt
fc
activ
sialat
esteras
expect
remov
sialic
acid
ncl
inde
shown
fig
middl
panel
lectin
part
protein
longer
abl
bind
ncl
esteras
moieti
cleav
group
bind
mut
fc
nontreat
ncl
detect
expect
kda
ncl
glycoform
express
surfac
preb
cell
identif
ncl
sialoglycoprotein
import
losfeld
et
al
demonstr
glycosyl
need
express
ncl
cell
surfac
moreov
bate
et
al
hypothes
normal
cell
transient
express
ncl
outsid
nucleu
respons
specif
stimuli
wherea
cancer
cell
would
hijack
express
nonnuclear
ncl
constitut
place
specif
signific
glycosyl
ncl
plasma
membran
cancer
cell
engag
transport
varieti
cargo
therefor
examin
cell
surfac
ncl
preb
cell
detail
base
western
blot
fig
compar
left
right
panel
confirm
kda
ncl
core
protein
exclus
detect
cytoplasm
membran
fraction
cell
surfac
ncl
appar
molecular
mass
kda
nonbiotinyl
intracellular
protein
fraction
also
contain
kda
ncl
protein
could
repres
glycosyl
ncl
differ
endocyt
compart
use
flow
cytometri
quantit
percentag
preb
cell
express
ncl
cell
surfac
ncl
rapid
turnov
plasma
membran
cell
fix
antibodi
stain
detect
locat
analysi
show
preb
popul
differ
percentag
cell
ncl
surfac
fig
exampl
lowest
percentag
wherea
preb
popul
cell
posit
mean
fluoresc
intens
mfi
measur
number
ncl
molecul
per
cell
compar
among
differ
preb
all
shown
indic
similar
level
ncl
express
cell
express
interestingli
cultur
seem
contain
discret
popul
either
express
express
cell
surfac
ncl
percentag
cell
posit
cell
surfac
ncl
appear
rel
stabl
properti
individu
preb
sampl
cell
multipl
occas
gave
consist
result
fig
agreement
result
western
blot
intracellular
ncl
fig
addit
permeabil
step
also
detect
intracellular
ncl
preb
all
almost
posit
ncl
shown
determin
whether
tissu
cultur
affect
ncl
express
preb
cell
also
assess
ncl
two
primari
viabli
frozen
bone
marrow
bm
one
fresh
peripher
blood
pb
preb
patient
sampl
compar
run
experi
noncultur
preb
cell
primari
pb
sampl
show
high
percentag
cell
surfac
ncl
fig
mfi
measur
number
ncl
molecul
per
cell
compar
cultur
preb
all
support
concept
preb
popul
mainli
differ
percentag
cell
express
ncl
differ
popul
compar
express
level
cell
two
preb
bm
sampl
cell
posit
cell
surfac
ncl
shown
also
evalu
cell
surfac
ncl
normal
nonleukem
human
preb
cell
character
posit
includ
posit
control
summar
fig
supplementari
fig
percentag
normal
preb
cell
express
surfac
ncl
vari
differ
donor
sampl
ncl
cell
surfac
partli
coloc
total
differ
cancer
cell
type
express
characterist
vari
percentag
cell
surfac
oacetyl
sialoglycoprotein
detect
specif
viral
hefc
lectin
next
measur
cell
surfac
preb
cell
use
fac
hefc
lectin
antihuman
igg
fcfitc
secondari
antibodi
shown
fig
larg
differ
among
preb
all
percentag
cell
posit
surfac
rang
nearli
cell
cell
preb
examin
sever
independ
experi
larg
variat
percentag
posit
cell
measur
fig
interestingli
preb
sampl
highli
posit
surfac
tend
also
highli
posit
cell
surfac
ncl
compar
fig
fig
coloc
signal
ncl
investig
use
imagestream
flow
cytometri
fig
signal
appear
punctat
structur
surfac
preb
cell
part
ncl
signal
also
concentr
punctat
structur
coloc
ncl
evid
area
plasma
membran
fig
arrow
merg
cell
analyz
clearli
posit
ncl
small
percentag
cell
singli
posit
ncl
locat
also
compar
normal
human
bone
marrow
preb
precursor
consist
fig
fig
show
fewer
normal
precursor
b
cell
express
cell
surfac
ncl
leukem
preb
cell
moreov
averag
around
normal
preb
cell
express
ncl
cell
compar
around
preb
cell
interestingli
wherea
around
preb
cell
posit
ncl
coloc
two
signal
case
normal
doubl
posit
preb
cell
taken
togeth
suggest
ncl
normal
preb
cell
contain
less
directli
compar
level
ncl
locat
cell
surfac
intracellularli
leukemia
cell
biotinyl
cell
surfac
protein
cell
similar
amount
immunoprecipit
ncl
cell
surfac
intracellular
fraction
compar
fig
bottom
panel
ncl
western
blot
use
porcin
mut
detect
probe
signal
lane
cell
surfac
ncl
stronger
lane
intracellular
ncl
indic
cell
surfac
sialyl
ncl
preferenti
compar
intracellular
ncl
fig
top
panel
use
stromal
cell
support
longterm
growth
viabil
preb
cell
cell
surfac
ncl
level
also
report
correl
cell
stimul
growth
eg
use
fac
compar
ncl
level
preb
cell
held
circumst
promot
cell
growth
howev
cell
surfac
ncl
level
reproduc
differ
preb
cell
grown
stroma
complet
growth
medium
preb
cell
incub
complet
medium
without
stroma
hr
preb
cell
kept
overnight
cultur
medium
without
fb
data
shown
also
analyz
cell
surfac
cytoplasm
ncl
preb
cell
without
stromal
support
use
western
blot
shown
fig
stromal
cell
alon
contain
compar
low
level
ncl
whether
preb
cell
kept
suspens
adher
cell
littl
effect
ncl
total
level
sialyl
ncl
subcellular
distribut
fig
per
lysat
ncl
present
cytosol
membran
fraction
yet
signal
porcin
mut
fc
bovin
mut
fc
detect
kda
ncl
stronger
cell
surfac
fraction
intracellular
fraction
taken
togeth
result
indic
cell
surfac
ncl
carri
intracellular
kda
ncl
also
perform
time
cours
preb
cell
treat
chemotherapeut
drug
vincristin
presenc
stromal
support
treatment
typic
result
persist
small
number
preb
cell
unabl
prolifer
fig
surviv
presenc
drug
measur
increas
percentag
live
trypanblu
exclud
cell
total
remain
popul
fig
illustr
fig
detect
increas
cell
surfac
ncl
preb
cell
surviv
previous
show
preb
cell
surviv
chemotherapi
increas
cell
surfac
sialoglycoprotein
report
cca
lectin
consist
also
measur
increas
level
preb
cell
use
porcin
mut
fc
interestingli
ncl
express
surfac
clearli
correl
cell
divis
cell
prolifer
rapidli
inhibit
vincristin
cell
surfac
ncl
persist
even
increas
time
fig
investig
regul
ncl
surfac
preb
cell
treat
cell
cholesteroldeplet
methyl
report
caus
redistribut
cell
surfac
ncl
lipid
raft
nonlipid
raft
also
treat
cell
extern
cacl
induc
endocytosi
cell
surfac
ncl
shown
fig
compar
control
treatment
correl
signific
increas
cell
surfac
ncl
treatment
ca
reduc
ncl
cell
surfac
treatment
preb
all
bovin
wt
fc
encod
activ
associ
small
increas
around
experi
cell
surfac
ncl
detect
compar
control
cell
shown
detect
glycosyl
kda
ncl
intracellularli
cell
surfac
use
western
blot
specif
address
effect
sialyl
pool
ncl
cell
surfac
treat
live
preb
cell
c
perfringen
sialidas
remov
sia
ncl
expos
cell
surfac
shown
fig
mark
increas
cell
surfac
ncl
detect
fac
enzymat
remov
sia
increas
cell
surfac
level
ncl
sialidas
treatment
unexpect
investig
detail
time
cours
treatment
carri
control
held
pb
without
sialidas
shown
fig
graphic
represent
fig
even
oneminut
incub
min
sialidas
increas
percentag
cell
posit
cell
surfac
ncl
compar
control
maximum
percentag
preb
cell
posit
cell
surfac
ncl
even
increas
min
also
test
effect
treatment
cell
surfac
report
bovin
mut
fc
measur
fac
supplementari
fig
level
structur
cell
surfac
measur
regul
ca
treatment
expect
wt
fc
destroy
bind
abil
lectin
part
sialidas
treatment
similar
effect
investig
ncl
could
therapeut
target
preb
treat
leukemia
cell
widelystudi
nclspecif
aptam
control
interestingli
hr
treatment
cell
surfac
ncl
decreas
cell
fig
cell
treat
hr
cell
prolifer
viabil
significantli
inhibit
compar
control
howev
concentr
much
smaller
effect
cell
fig
c
treatment
preb
all
similarli
show
differenti
sensit
ncl
inhibit
supplementari
fig
respond
treatment
inhibit
cell
divis
caus
cell
death
prolifer
similar
inhibit
strongest
effect
cytostat
cytotox
effect
measur
identifi
ncl
sialoglycoprotein
modifi
preb
ncl
studi
preb
although
view
possibl
target
treatment
cancer
context
subcellular
locat
distribut
ncl
protein
appear
key
factor
see
normal
cell
report
express
ncl
mainli
nucleu
wherea
cancer
cell
constitut
express
ncl
cell
surfac
thu
question
regul
express
ncl
surfac
cell
signific
interest
hovanessian
et
al
show
ncl
need
glycosyl
appear
surfac
indic
cancer
cell
express
high
level
cell
surfac
ncl
must
also
maintain
high
glycosyl
level
ncl
hovanessian
et
al
also
report
halflif
cytoplasm
cell
surfac
ncl
carcinoma
around
minut
cancer
cell
either
recycl
ncl
effici
minim
deglycosyl
rapidli
synthes
glycosyl
de
novo
regardless
exact
mechan
found
preb
cell
kda
glycosyl
ncl
core
kda
ncl
locat
surfac
agreement
report
previous
seven
potenti
glycosyl
site
identifi
ncl
includ
five
olink
glycosyl
site
ntermin
end
ncl
two
nlink
site
tall
jurkat
cell
found
kda
ncl
glycoprotein
band
contain
sia
sia
ncl
termin
nand
olink
glycan
kda
ncl
glycoform
bound
cca
lectin
complet
cleav
osgpas
ncl
contain
cluster
olink
sialic
acid
probabl
glycan
attach
ntermin
part
ncl
final
find
antibodi
rais
crossreact
sialyl
ncl
seen
suggest
ncl
could
contain
disial
acid
structur
although
common
report
glycoprotein
ncam
includ
leukocyt
common
antigen
summari
conclud
ncl
surfac
preb
cell
sialyl
sialyl
found
nand
olink
glycan
ncl
sialoglycoform
contain
cluster
olink
glycan
previou
studi
other
identifi
surfac
preb
cell
base
use
antibodi
also
wide
use
purpos
immunohistochemistri
fox
et
al
report
monoclon
antibodi
recogn
actual
detect
sialoglycoprotein
kda
mw
cell
jone
antibodi
react
also
detect
glycoprotein
kda
kda
rang
studi
mab
sold
antibodi
detect
glycoprotein
react
kda
protein
bind
cca
lectin
immunoprecipit
ncl
react
conclud
ncl
one
principl
oacetyl
sialoglycoprotein
detect
exclud
possibl
recogn
addit
oacetyl
sialoglycoprotein
kda
rang
sensit
sialic
acid
remov
treatment
c
perfringen
sialidas
prefer
sia
may
inhibit
thu
studi
use
antibodi
fac
report
presenc
gangliosid
cell
surfac
may
actual
also
even
mainli
detect
sia
modifi
glycoprotein
includ
ncl
although
signal
ncl
correl
bovin
mut
fc
clearli
detect
oacsia
bear
structur
ncl
preb
cell
visual
imagestream
analysi
convers
cell
surfac
ncl
coloc
signal
support
biochem
analysi
substanti
amount
glycosyl
kda
ncl
found
flowthrough
cca
lectin
bovin
mut
porcin
mut
affin
column
thu
although
clearli
constitut
part
structur
detect
lectin
sialyl
ncl
modifi
structur
ncl
therefor
surpris
increas
extracellular
ca
lipid
raft
disrupt
markedli
affect
cell
surfac
ncl
minim
chang
structur
also
investig
sialyl
cell
surfac
ncl
regul
locat
found
surprisingli
brief
treatment
c
perfringen
sialidas
caus
increas
ncl
level
detect
plasma
membran
principl
desialyl
increas
access
epitop
recogn
antincl
antibodi
howev
western
blot
antibodi
detect
sialyl
nonsialyl
ncl
ncl
short
retent
time
cell
surfac
detect
increas
level
could
caus
decreas
endocytosi
acceler
exocytosi
exampl
remov
termin
sia
could
expos
glycan
ncl
subsequ
bound
crosslink
lectin
prevent
endocytosi
ncl
sequestr
outsid
lipid
raft
increas
exocytosi
could
also
play
role
sialyl
decreas
exocytosi
lysosom
sialoglycoprotein
howev
unlik
c
perfringen
sialidas
enter
preb
cell
remov
sia
intracellular
ncl
therefor
stimulatori
effect
enzym
put
ncl
exocytosi
via
lysosomalendosom
rout
improb
altern
lipid
raft
partit
may
regul
sialyl
state
ncl
oglycosyl
cell
surfac
protein
includ
need
sialyl
abl
associ
lipid
raft
disrupt
lipid
raft
use
sialidas
treatment
caus
increas
retent
ncl
surfac
altern
explan
sialidas
treatment
decreas
ncl
locat
lipid
raft
mechan
delay
endocytosi
ncl
view
therapeut
target
cancer
although
express
restrict
malign
cell
base
gene
array
express
data
preb
all
differ
subcategori
express
high
level
ncl
mrna
significantli
higher
normal
control
preb
cell
except
mll
subcategori
supplementari
fig
also
detect
cell
surfac
ncl
protein
normal
precursor
b
cell
although
lower
level
malign
preb
cell
studi
shown
ncl
directli
indirectli
regul
express
larg
number
gene
normal
hematopoiesi
mahotka
et
al
found
signific
chang
level
around
express
gene
overexpress
ncl
normal
human
hematopoiet
stem
cell
nonetheless
review
bate
et
al
numer
antincl
therapeut
includ
aptam
deriv
extens
use
even
evalu
clinic
trial
shown
surprisingli
low
system
toxic
anim
model
human
indic
interfer
ncl
activ
normal
cell
consequ
altern
therapeut
window
consist
differenti
express
level
cell
surfac
normal
malign
cell
context
import
note
therapeut
antincl
antibodi
complet
depend
ncl
plasma
membran
abl
stimul
antibodydepend
cytotox
immun
effector
cell
therapeut
presenc
absenc
ncl
cell
surfac
critic
factor
result
also
tent
suggest
link
locat
ncl
plasma
membran
sensit
preb
all
markedli
less
affect
preb
all
among
preb
all
lowest
percentag
cell
ncl
cell
surfac
express
convers
highest
sensit
also
high
percentag
cell
surfac
ncl
thu
therapeut
antincl
perspect
prolong
ncl
occup
retent
time
cell
surfac
would
desir
although
found
sialidas
treatment
preb
cell
would
produc
effect
treatment
appli
therapi
contrast
find
vincristin
convent
chemotherapeut
also
produc
effect
suggest
combin
treatment
vincristin
antincl
agent
antincl
antibodi
may
effect
treatment
singl
agent
cell
cultur
cell
murin
stromal
cell
line
human
acut
lymphoblast
leukemia
cell
line
obtain
american
type
cultur
collect
human
preb
all
studi
includ
previous
describ
leukemia
cell
cocultur
irradi
mitot
inactiv
cell
medium
supplement
fb
lglutamin
penicillinstreptomycin
life
technolog
grand
island
ny
human
specimen
collect
protocol
review
approv
children
hospit
lo
angel
institut
review
board
irb
committe
clinic
investig
cci
sampl
collect
obtain
written
inform
consent
andor
leftov
specimen
initi
collect
clinic
diagnost
purpos
discard
medic
wast
longer
need
clinic
purpos
specimen
deidentifiedanonym
acquisit
research
collect
experi
perform
accord
irb
guidelin
regul
approv
red
blood
cell
lysi
mononuclear
cell
collect
ficol
centrifug
immedi
analyz
viabli
frozen
isol
normal
human
preb
precursor
viabli
frozen
enrich
normal
human
bone
marrow
sampl
thaw
process
releas
human
posit
select
kit
human
posit
select
kit
stemcel
technolog
vancouv
bc
canada
cancer
antennariu
lectin
california
crab
cca
lectin
purchas
ey
laboratori
inc
san
mateo
ca
usa
porcin
toroviru
bovin
coronaviru
bcovmebu
hemagglutininesteras
hefc
probe
includ
wild
type
esteras
activ
wt
fc
mutant
esteras
inact
bind
activ
sialic
acid
mut
fc
gener
describ
use
lectin
affin
column
chromatographi
lectin
biotinyl
ezlink
tm
sulfonhslcbiotin
thermo
fisher
scientif
waltham
usa
accord
manufactur
instruct
biotinyl
lectin
incub
prewash
dynabead
streptavidin
invitrogen
waltham
usa
hr
assembl
lectinmagnet
bead
complex
cca
lectin
affin
column
lysat
triton
lysi
buffer
tx
buffer
mm
nacl
mm
tri
ph
triton
glycerol
mm
edta
proteas
phosphatas
inhibitor
roch
basel
switzerland
dilut
bind
buffer
contain
mm
trishcl
ph
mm
nacl
mm
calcium
chlorid
incub
lectinmagnet
bead
complex
overnight
rotat
sever
wash
bind
buffer
mixtur
react
elut
buffer
mm
sodium
citrat
bind
buffer
elut
target
protein
hr
flowthrough
wash
eluat
fraction
concentr
via
centrifug
filter
mwco
amicon
emd
millipor
billerica
usa
proteom
analysi
concentr
elut
fraction
cca
lectin
affin
column
analyz
sdspage
visual
silver
stain
fig
coomassi
stain
kda
band
interest
cut
coomassiestain
gel
analyz
univers
southern
california
proteom
core
facil
hefc
affin
column
total
lysat
preb
cell
incub
biotinyl
mut
fc
probe
overnight
rotat
follow
immobil
magnet
bead
addit
hr
sever
wash
elut
fraction
analyz
western
blot
examin
glycosyl
ncl
elut
fraction
cca
lectin
affin
column
incub
osialoglycoproteas
osgpas
cedarlan
burlington
nc
peptid
nglycosidas
f
pngase
f
new
england
biolab
ipswich
sialidas
clostridium
perfringen
sigma
st
loui
mo
hr
overnight
accord
manufactur
instruct
digest
sampl
concentr
subject
western
blot
use
cell
pb
per
condit
studi
cell
surfac
ncl
cell
surfac
variou
condit
treatment
includ
bovin
wt
fc
mu
sialidas
mm
methyl
betacyclodextrin
mm
cacl
mm
egta
hr
wash
twice
pb
cell
analyz
flow
cytometri
timecours
sialidas
treatment
preb
cell
fig
fig
oacetyl
monoclon
antibodi
cat
invitrogen
grand
island
ny
antibodi
cat
abcam
also
porcin
toroviru
bovin
coronaviru
mut
fc
use
immunoblot
western
blot
membran
antibodi
cat
santa
cruz
biotechnolog
use
load
control
regular
immunoprecipit
lysat
incub
mous
antincl
cat
santa
cruz
biotechnolog
overnight
igg
neg
control
follow
addit
incub
preclear
protein
g
hr
rotat
denatur
ip
product
subject
western
blot
analyz
cell
surfac
cytoplasm
preb
cell
biotinyl
ten
fifti
million
cell
wash
cold
dpb
biotinyl
hr
lyse
tx
lysi
buffer
prewash
neutravidin
agaros
pierc
waltham
incub
biotinyl
cell
lysat
hr
gentl
rotat
first
centrifug
supernat
collect
intracellular
fraction
resin
wash
tx
buffer
sever
time
cell
surfac
fraction
glycin
ph
ad
resin
incub
min
reaction
neutral
ad
tri
ph
fraction
intracellular
cell
surfac
use
standard
immunodetect
ip
flow
cytometri
imag
stream
cell
surfac
ncl
measur
flow
cytometri
ncl
monoclon
antibodi
cat
label
use
mixnstain
cf
antibodi
label
kit
sigma
st
loui
mo
mutant
bovin
porcin
mut
fc
probe
allow
bind
cell
surfac
first
fitc
antihuman
fc
igg
antibodi
cat
biolegend
san
diego
ca
use
detect
bind
follow
preb
cell
first
block
use
human
fcr
block
reagent
cat
mac
milteni
biotec
san
diego
ca
fix
ic
fixat
buffer
cat
ebiosci
waltham
min
rt
cell
next
incub
antibodi
probe
per
cell
hr
analyz
accuri
cytomet
bd
bioscienc
san
jose
ca
control
cell
stain
isotypematch
igg
conjug
fluorophor
iggfitc
incub
secondari
antibodi
lectin
experi
perform
twothre
time
independ
everi
evalu
cell
surfac
ncl
viabli
frozen
normal
human
bone
marrow
sampl
cell
block
fix
incub
follow
antibodi
fitc
antihuman
cat
clone
biolegend
apc
antihuman
cat
clone
biolegend
pe
antihuman
cat
clone
bd
bioscienc
ncl
cat
clone
santa
cruz
porcin
mut
fc
follow
fitc
antihuman
fc
igg
antibodi
cell
analyz
use
lsr
fortessatm
bd
franklin
lake
nj
percentag
popul
posit
cell
surfac
ncl
calcul
gate
doubleposit
popul
imag
coloc
cell
surfac
ncl
cell
block
fix
costain
mut
fc
follow
analysi
imag
stream
imagestream
x
mark
ii
imag
flow
cytomet
amni
emd
millipor
billerica
imag
file
event
acquir
idea
softwar
use
analyz
coloc
ncl
plasma
membran
cell
posit
drug
treatment
cell
cocultur
irradi
plate
presenc
nm
vincristin
indic
time
period
fresh
media
drug
suppli
everi
day
total
cell
number
cell
viabil
determin
use
trypan
blue
exclus
fac
use
evalu
cell
surfac
level
ncl
drug
treatment
treatment
carri
triplic
sampl
three
independ
experi
nclspecif
treatment
control
aptam
obtain
invitrogen
idt
coralvil
iowa
cell
incub
variou
concentr
indic
hr
trypan
blue
exclus
use
count
live
cell
statist
analysi
statist
analysi
perform
prism
softwar
data
present
mean
se
statist
signific
differ
group
evalu
use
student
ttest
oneway
twoway
anova
indic
valu
p
consid
statist
signific
